Syros Pharmaceuticals Inc.
NASDAQ:SYRS 4:00:00 PM EDT
Products
Syros Receives Fast Track Designation From FDA For Tamibarotene
Published: 01/26/2023 12:37 GMT
Syros Pharmaceuticals Inc. (SYRS) - Syros Receives Fast Track Designation From the FDA for Tamibarotene for the Treatment of Higher-risk Myelodysplastic Syndrome.
Syros Pharmaceuticals Inc - Expects to Complete Patient Enrollment in Select-mds-1 in Q4 of 2023, With Pivotal Data Expected in Q3 of 2024.
Syros Pharmaceuticals - Initial Data From Randomized Portion of Select-aml-1 Phase 2 Trial Expected in Q4 of 2023 and Additional Data in 2024.
Syros Pharmaceuticals Inc - Expects to Complete Patient Enrollment in Select-mds-1 in Q4 of 2023, With Pivotal Data Expected in Q3 of 2024.
Syros Pharmaceuticals - Initial Data From Randomized Portion of Select-aml-1 Phase 2 Trial Expected in Q4 of 2023 and Additional Data in 2024.